Who are Tazverik's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tazverik, Ongentys, Comtan, Azacytidine, HAG Regimen, Azacitidine (AZA), Azacitidine Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl3414621.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tazverik — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tazverik (TAZEMETOSTAT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Methyltransferase Inhibitor. Area: Oncology.

marketed Methyltransferase Inhibitor Polycomb protein EED Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tazverik (TAZEMETOSTAT) — Epizyme Inc. Tazverik works by blocking the action of an enzyme called EED, which is involved in the production of proteins that promote cancer growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tazverik TARGET	TAZEMETOSTAT	Epizyme Inc	marketed	Methyltransferase Inhibitor	Polycomb protein EED	2020-01-01
Tazverik	tazemetostat	Epizyme Inc	marketed	Methyltransferase Inhibitor	Polycomb protein EED	2020-01-01
Ongentys	BIA 9-1067	Neurocrine Biosciences	marketed	Catechol-O-Methyltransferase Inhibitor [EPC]	Catechol O-methyltransferase	2020-01-01
Comtan	ENTACAPONE	Orion Pharma	marketed	Catechol-O-Methyltransferase Inhibitor [EPC]	Catechol O-methyltransferase	1999-01-01
Azacytidine, HAG Regimen	Azacytidine, HAG Regimen	Shenzhen Second People's Hospital	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Azacitidine (AZA)	Azacitidine (AZA)	Memorial Sloan Kettering Cancer Center	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Azacitidine Injection	Azacitidine Injection	Ascentage Pharma Group Inc.	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-26 — Ongentys · 9550759 · US
2027-05-12 — Ongentys · 8907099 · US
2027-10-10 — Ongentys · 9745290 · US
2029-04-02 — Ongentys · 8168793 · US
2029-07-14 — Ongentys · 8524746 · US
2030-03-31 — Ongentys · 10071085 · US
2030-03-31 — Ongentys · 10583130 · US
2032-12-12 — Ongentys · 9630955 · US
2035-05-27 — Ongentys · 10357468 · US

Sponsor landscape (Methyltransferase Inhibitor class)

Epizyme Inc · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tazverik — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl3414621. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab